Abstract: The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.

Abstract: The instant invention provides an isocyanate trimerization catalyst system, a precursor formulation, a process for trimerizing isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerization catalyst system comprises: (a) a phosphatrane cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerization catalyst system has a trimerization activation temperature in the range of equal to or less than 73° C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerization catalyst system, based on the weight of the precursor formulation, comprising; (a) a phosphatrane cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerization catalyst system has a trimerization activation temperature in the range of equal to or less than 73° C.

Abstract: A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.

Abstract: The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si—HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.

Abstract: Embodiments of the present disclosure include a method of separating an oil-in-water emulsion formed during crude oil production into a water phase and an oil phase that includes adding 1 part-per-million (ppm) to 10000 ppm of a cationic vinyl imidazolium-based copolymer to the oil-in-water emulsion, based on the total volume of the oil-in-water emulsion, to form a water phase and an oil phase, and separating the water phase from the oil phase.

Abstract: The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphatrane cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) a phosphatrane cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.

Abstract: Embodiments of the present disclosure include a method of separating an oil-in-water emulsion formed during crude oil production into a water phase and an oil phase that includes adding 1 part-per-million (ppm) to 10000 ppm of an N-vinylpyrrolidone based cationic copolymer to the oil-in-water emulsion, based on the total volume of the oil-in-water emulsion, to form a water phase and an oil phase, and separating the water phase from the oil phase.

Abstract: A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.

Abstract: A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.

Abstract: The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. A trimerisation catalyst system comprising (a) a phosphonium cation; and (b) an isocyanate-trimer inducing carboxylate anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. is provided.

Abstract: A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.

Abstract: A curable composition comprising a blend of: a) an epoxy resin; and b) a hardener comprising a polyfunctional amine is disclosed. The curable composition can be used in a variety of applications including, but not limited to coatings, civil engineering, flooring, composites, adhesives, and electrical laminates.

Abstract: Embodiments of the present disclosure include a method of separating an oil-in-water emulsion formed during crude oil production into a water phase and an oil phase that includes adding 1 part-per-million (ppm) to 10000 ppm of an N-vinylpyrrolidone based cationic copolymer to the oil-in-water emulsion, based on the total volume of the oil-in-water emulsion, to form a water phase and an oil phase, and separating the water phase from the oil phase.

Abstract: Embodiments of the present disclosure include a method of separating an oil-in-water emulsion formed during crude oil production into a water phase and an oil phase that includes adding 1 part-per-million (ppm) to 10000 ppm of a cationic vinyl imidazolium-based copolymer to the oil-in-water emulsion, based on the total volume of the oil-in-water emulsion, to form a water phase and an oil phase, and separating the water phase from the oil phase.

Abstract: A balloon catheter system configured to deliver one or more stimulation signal to a tissue comprises an expandable balloon disposed around a distal portion of a catheter, a plurality of electrodes, and an external sheath having a lumen sized to slidably accommodate the expandable balloon, catheter and the plurality of electrodes. The plurality of electrodes are flexibly distributed along a balloon length and are configured to deliver the stimulation signals to the tissue. The plurality of electrodes may preferably be disposed on a flexible frame coupled externally of the expandable balloon and in sliding engagement to the balloon during inflation and deflation. The flexible frame may further comprise one or more sensors. The external sheath is made of a non-conductive material and is configured to prevent delivery of the stimulation signals by the electrodes disposed along an inoperable length of the expandable balloon when the balloon is inflated.

Abstract: Embodiments of the invention provide for a polycarbonate polyol including the reaction product of at least one polyol composition and a carbonate. The polycarbonate is one of an amorphous liquid and an amorphous solid at room temperature. The polyol composition includes at least one of a mixture of 1,3-cyclohexanedimethanol and 1,4-cyclohexanedimethanol in a weight ratio from about 60:40 to about 5:95 and a polyol derived from a natural oil fatty acid or natural oil fatty acid methyl ester.

Abstract: A balloon catheter system configured to deliver one or more stimulation signal to a tissue comprises an expandable balloon disposed around a distal portion of a catheter, a plurality of electrodes, and an external sheath having a lumen sized to slidably accommodate the expandable balloon, catheter and the plurality of electrodes. The plurality of electrodes are flexibly distributed along a balloon length and are configured to deliver the stimulation signals to the tissue. The plurality of electrodes may preferably be disposed on a flexible frame coupled externally of the expandable balloon and in sliding engagement to the balloon during inflation and deflation. The flexible frame may further comprise one or more sensors. The external sheath is made of a non-conductive material and is configured to prevent delivery of the stimulation signals by the electrodes disposed along an inoperable length of the expandable balloon when the balloon is inflated.

Abstract: The present invention relates to compositions, kits and methods for the administration of various vitamin, mineral and nutrient compositions, and in a specific embodiment, the compositions, kits and methods may utilize or include twelve carbon chain fatty acids and/or twelve carbon chain acylglycerols, vitamin D, iodine, vitamin B1, vitamin B6, vitamin B12, vitamin B2, vitamin B9, vitamin B3, vitamin E, vitamin A, vitamin C, iron, zinc, copper, magnesium, omega 3 fatty acids and one or more pharmaceutically acceptable carriers.

Abstract: The present invention relates to compositions, kits and methods for the administration of various vitamin, mineral and nutrient compositions, and in a specific embodiment, the compositions, kits and methods may utilize or include twelve carbon chain fatty acids and/or twelve carbon chain acylglycerols, vitamin D, iodine, vitamin B1, vitamin B6, vitamin B12, vitamin B2, vitamin B9, vitamin B3, vitamin E, vitamin A, vitamin C, iron, zinc, copper, magnesium, omega 3 fatty acids and one or more pharmaceutically acceptable carriers.

Abstract: The present invention relates to compositions, kits and methods for the administration of compositions and kits for supplementation with twelve carbon chain fatty acids or twelve carbon chain acylglycerols; and specifically for the supplementation with twelve carbon chain fatty acids such as lauric acid and twelve carbon chain acylglycerols such as monolaurin; and specifically for the co-supplementation with other vitamins, minerals and nutrients.